What changed in Labcorp Holdings Inc.'s latest annual report
In the year ended 31 Dec 2025, Labcorp Holdings Inc.'s revenue rose 7.2% to USD 13.95bn, from USD 13.01bn; net income rose 17.5% to USD 876.50m, from USD 746.00m; cash and cash equivalents fell 65% to USD 532.30m, from USD 1.52bn.
Year ended 31 Dec 2025. Source: 10-K filed 24 Feb 2026, read it on SEC EDGAR.
USD 13.01bn to USD 13.95bn
The figures, year on year
| Item | Year before | Latest year | Change |
|---|---|---|---|
| Revenue | 13.01bn | 13.95bn | Up 7.2% |
| Net income | 746.00m | 876.50m | Up 17.5% |
| Total assets | 18.38bn | 18.39bn | Up 0.1% |
| Total liabilities | 10.31bn | 9.76bn | Down 5.4% |
| Long-term debt | 5.33bn | 5.08bn | Down 4.6% |
| Cash and cash equivalents | 1.52bn | 532.30m | Down 65% |
| Shareholders' equity | 8.05bn | 8.62bn | Up 7% |
Questions people ask
Did Labcorp Holdings Inc.'s revenue grow last year?
Revenue grew 7.2%, from USD 13.01bn to USD 13.95bn in the year ended 31 Dec 2025.
Is Labcorp Holdings Inc. profitable?
Yes. Net income was USD 876.50m in the year ended 31 Dec 2025. The year before: USD 746.00m.
How much cash and debt does Labcorp Holdings Inc. have?
At its latest year end (31 Dec 2025), Labcorp Holdings Inc. reported cash and cash equivalents of USD 532.30m and long-term debt of USD 5.08bn.
Where do these numbers come from?
From Labcorp Holdings Inc.'s own annual filings with the SEC. Each change is calculated from the reported figures; nothing is estimated.
Meeting a client who works with Labcorp Holdings Inc.?
LYNORIQ remembers every client meeting the way this page tracks a filing: what changed since last time, what you promised, and what they owe you.
Start free See the demoOther Services-Medical Laboratories companies
- Natera, Inc.Total liabilities up 47.4%
- Quest Diagnostics IncCash and cash equivalents down 23.5%
- Guardant Health, Inc.Total assets up 35.5%